国发股份(600538) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was CNY 114,533,611.38, representing a year-on-year increase of 79.27%[5]. - The net profit attributable to shareholders for the same period was CNY 3,199,199.99, with a year-to-date net profit of CNY 7,804,270.87, reflecting a significant increase due to the acquisition of GaoSheng Bio[5][9]. - Total operating revenue for the first three quarters of 2021 reached ¥304,631,870.81, a significant increase of 68% compared to ¥181,341,788.70 in the same period of 2020[25]. - The net profit for the third quarter of 2021 was CNY 8,304,358.54, a significant recovery from a net loss of CNY 5,301,691.17 in the same period of 2020, representing a turnaround of over 200%[27]. - Operating profit for the third quarter reached CNY 12,474,974.14, compared to an operating loss of CNY 3,305,567.72 in Q3 2020, indicating a strong operational improvement[27]. - The total profit for the third quarter was CNY 12,790,001.66, a significant increase from a total loss of CNY 3,472,346.58 in Q3 2020, indicating a strong recovery in profitability[27]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,070,138,391.85, a slight increase of 0.11% compared to the end of the previous year[6]. - Total liabilities decreased to ¥147,920,453.49 as of September 30, 2021, down from ¥217,265,963.49 at the end of 2020, a reduction of approximately 32%[24]. - The company's total assets stood at ¥1,070,138,391.85 as of September 30, 2021, slightly up from ¥1,068,937,499.81 at the end of 2020[23]. - Total current liabilities were approximately CNY 216.57 million, with accounts payable at CNY 44.19 million[36]. - Total liabilities amounted to approximately CNY 219.21 million, indicating a minor increase[36]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,756[11]. - The largest shareholder, Zhu Rongjuan, holds 105,110,542 shares, accounting for 20.05% of total shares, with 104,960,000 shares pledged[11]. - Shareholder Yao Fangyuan reduced her holdings by 7 million shares, representing 1.34% of the total share capital[16]. - Chairman Pan Libin plans to reduce his holdings by up to 3,450,000 shares, which is 0.675% of the total share capital[17]. - As of September 30, 2021, the total number of pledged shares by major shareholders is 104,960,000 shares[19]. - The company’s major shareholder, Guangxi Guofa Investment Group, has pledged 27,325,000 shares[19]. Cash Flow and Investments - Cash flow from operating activities showed a negative net amount of CNY -46,142,961.55 year-to-date, indicating a decrease in cash inflow[5][9]. - The cash flow from operating activities showed a net outflow of CNY 46,142,961.55 in the first nine months of 2021, contrasting with a net inflow of CNY 3,346,151.16 in the same period of 2020[31]. - The company experienced a net cash outflow from investing activities of CNY 89,303,266.00 in the first nine months of 2021, compared to a net outflow of CNY 31,134,322.39 in the same period of 2020[32]. - The company raised CNY 67,799,987.40 from financing activities in the first nine months of 2021, compared to a net outflow of CNY 2,430,991.60 in the same period of 2020[32]. - The company invested RMB 10 million in Youfeng (Beijing) Biotechnology Co., Ltd., acquiring a 1% stake[15]. Operational Metrics - The company reported a significant increase in accounts receivable, up 252.78%, primarily due to receiving more commercial acceptance bills[8]. - The increase in operating costs year-to-date was 55.61%, attributed to the consolidation of GaoSheng Bio's financials[8]. - The company's basic earnings per share for Q3 2021 was CNY 0.01, unchanged from the previous year[5]. - The company’s weighted average return on equity was 0.29% for the quarter[5]. - The gross profit margin for the first three quarters of 2021 was approximately 5.3%, compared to 0.1% in the same period of 2020[25]. - Research and development expenses for the first three quarters of 2021 were ¥5,110,633.85, significantly higher than ¥22,844.21 in the same period of 2020, indicating a strategic focus on innovation[25]. Capital Structure - The company completed a private placement of 12,427,005 shares, raising a net amount of RMB 61,799,695.43, increasing registered capital to RMB 524,198,348[13]. - The company completed a non-public offering to raise funds, which contributed to its financing activities[9]. - The company has completed the registration procedures for the newly issued shares on July 28, 2021[13].